Nearly 100,000 patients with Alzheimer's a year will be refused drugs that could delay the onset of the disease, the Court of Appeal has heard. The manufacturer of one drug - Aricept - has been fighting a decision to restrict access to patients in the later stages of the disease. NHS drugs advisers said the therapy along with others in its class are not cost effective for early Alzheimer's.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment